Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of sprinkled vs intact lomitapide
NCT02044419Phase 1Completed
- Sponsor
- Aegerion Pharmaceuticals
- Start
- Oct 2013
- Primary completion
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lomitapide in homozygous familial hypercholesterolemia (HoFH) (3 arms), sponsored by Aegerion Pharmaceuticals. Primary endpoints: Area Under the Curve from time 0 to the last measurable concentration, Maximum Plasma Concentration and 4 more. Started Oct 2013; status: completed.
02
Drugs
lomitapide
03
Conditions
homozygous familial hypercholesterolemia (HoFH)
Beyond the preview
Go deeper on NCT02044419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02044419.